MiMedx Group, Inc. (MDXG) Reaches $7.79 After 8.00% Up Move; Antero Midstream Partners LP (AM) Covered By 16 Bullish Analysts Last Week

May 4, 2018 - By Richard Conner

MiMedx Group, Inc. (NASDAQ:MDXG) Logo

The stock of MiMedx Group, Inc. (NASDAQ:MDXG) is a huge mover today! The stock increased 3.32% or $0.25 during the last trading session, reaching $7.79. About 333,164 shares traded. MiMedx Group, Inc. (NASDAQ:MDXG) has declined 27.63% since May 4, 2017 and is downtrending. It has underperformed by 39.18% the S&P500.The move comes after 5 months positive chart setup for the $864.96M company. It was reported on May, 4 by Barchart.com. We have $8.41 PT which if reached, will make NASDAQ:MDXG worth $69.20M more.

Among 19 analysts covering Antero Midstream Partners LP (NYSE:AM), 16 have Buy rating, 0 Sell and 3 Hold. Therefore 84% are positive. Antero Midstream Partners LP had 52 analyst reports since July 23, 2015 according to SRatingsIntel. On Monday, July 17 the stock rating was maintained by Stifel Nicolaus with “Buy”. The company was upgraded on Friday, April 29 by Credit Suisse. As per Thursday, March 17, the company rating was downgraded by Credit Suisse. The firm earned “Buy” rating on Thursday, October 12 by Robert W. Baird. The rating was maintained by Seaport Global with “Buy” on Thursday, February 15. Robert W. Baird maintained Antero Midstream Partners LP (NYSE:AM) rating on Wednesday, November 15. Robert W. Baird has “Buy” rating and $42.0 target. The stock of Antero Midstream Partners LP (NYSE:AM) earned “Hold” rating by Stifel Nicolaus on Tuesday, May 30. The stock of Antero Midstream Partners LP (NYSE:AM) has “Outperform” rating given on Thursday, June 9 by Robert W. Baird. The rating was maintained by Citigroup on Wednesday, March 28 with “Buy”. The stock of Antero Midstream Partners LP (NYSE:AM) has “Overweight” rating given on Tuesday, April 17 by Barclays Capital. See Antero Midstream Partners LP (NYSE:AM) latest ratings:

17/04/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $37 New Target: $36 Maintain
16/04/2018 Broker: Guggenheim Rating: Buy New Target: $34.0000 Maintain
09/04/2018 Broker: Robert W. Baird Rating: Buy New Target: $49.0000 Maintain
09/04/2018 Broker: Seaport Global Old Rating: Buy New Rating: Neutral Old Target: $37 New Target: $25 Downgrade
28/03/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $36 New Target: $33 Maintain
14/03/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $25 New Target: $23 Maintain
15/02/2018 Broker: Seaport Global Rating: Buy New Target: $37.0 Maintain
19/01/2018 Broker: Robert W. Baird Rating: Buy New Target: $43.0 Maintain
17/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $37 Maintain
05/01/2018 Broker: Credit Suisse Rating: Outperform New Target: $35 Initiates Coverage On

Antero Midstream Partners LP owns, operates, and develops midstream energy assets. The company has market cap of $4.86 billion. The firm operates in two divisions, Gathering and Processing, and Water Handling and Treatment. It has a 20.29 P/E ratio. The Company’s assets include 8-, 12-, 16-, 20-, and 24-inch high and low pressure gathering pipelines, compressor stations, and processing and fractionation plants that collect and process natural gas, natural gas liquids, and crude oil and condensate from wells in the Marcellus Shale in West Virginia and the Utica Shale in Ohio; and water handling and treatment assets, which comprise two independent fresh water delivery systems that deliver fresh water from the Ohio River and several regional waterways, as well as wastewater handling services for well completion operations.

Another recent and important Antero Midstream Partners LP (NYSE:AM) news was published by Globenewswire.com which published an article titled: “Research Report Identifies Antero Midstream Partners LP, Genesis Energy, NextEra Energy Partners, LP, Wabash …” on April 20, 2018.

The stock increased 0.82% or $0.21 during the last trading session, reaching $25.97. About 71,474 shares traded. Antero Midstream Partners LP (NYSE:AM) has declined 24.27% since May 4, 2017 and is downtrending. It has underperformed by 35.82% the S&P500.

Investors sentiment decreased to 1.07 in 2017 Q4. Its down 0.98, from 2.05 in 2017Q3. It worsened, as 15 investors sold Antero Midstream Partners LP shares while 39 reduced holdings. 17 funds opened positions while 41 raised stakes. 89.68 million shares or 0.88% less from 90.48 million shares in 2017Q3 were reported. Stifel Corporation has 0% invested in Antero Midstream Partners LP (NYSE:AM) for 23,603 shares. Chickasaw Capital Management Lc invested 2.85% in Antero Midstream Partners LP (NYSE:AM). Alps Advsrs, Colorado-based fund reported 7.27 million shares. First Republic Investment Mngmt Inc accumulated 38,858 shares. Citigroup has invested 0.02% in Antero Midstream Partners LP (NYSE:AM). Tower Research Capital Ltd Co (Trc) invested in 710 shares or 0% of the stock. Pathstone Family Office Limited Liability Company invested in 0.02% or 1,080 shares. Jpmorgan Chase & has invested 0.01% in Antero Midstream Partners LP (NYSE:AM). Mckinley Cap Mgmt Delaware holds 31,167 shares or 0.05% of its portfolio. Us Bancorporation De owns 10,391 shares. Kayne Anderson Advsr Lp has invested 1.08% in Antero Midstream Partners LP (NYSE:AM). Cbre Clarion Llc reported 117,608 shares or 0.04% of all its holdings. Cushing Asset Ltd Partnership has 371,734 shares. Raymond James And has invested 0% in Antero Midstream Partners LP (NYSE:AM). Duff And Phelps Inv Management Company owns 435,000 shares or 0.18% of their US portfolio.

MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. The company has market cap of $864.96 million. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. It has a 25.05 P/E ratio. The companyÂ’s proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.

Investors sentiment decreased to 1.01 in Q4 2017. Its down 0.96, from 1.97 in 2017Q3. It dropped, as 40 investors sold MiMedx Group, Inc. shares while 61 reduced holdings. 39 funds opened positions while 63 raised stakes. 86.17 million shares or 11.58% more from 77.22 million shares in 2017Q3 were reported. Lincoln National reported 30,380 shares. Employees Retirement Of Ohio has invested 0% in MiMedx Group, Inc. (NASDAQ:MDXG). Teacher Retirement Of Texas owns 0% invested in MiMedx Group, Inc. (NASDAQ:MDXG) for 36,451 shares. Stifel Corporation owns 10,728 shares. Hbk Investments Lp has 0.01% invested in MiMedx Group, Inc. (NASDAQ:MDXG) for 90,300 shares. Smithfield reported 0% in MiMedx Group, Inc. (NASDAQ:MDXG). Brown Advisory stated it has 652,737 shares. Comerica Natl Bank reported 0.01% of its portfolio in MiMedx Group, Inc. (NASDAQ:MDXG). Tiedemann Wealth Mgmt Limited Liability Corporation reported 1.45 million shares. Westwood Mgmt Corporation Il holds 0.45% of its portfolio in MiMedx Group, Inc. (NASDAQ:MDXG) for 255,000 shares. Oz Mgmt L P owns 0% invested in MiMedx Group, Inc. (NASDAQ:MDXG) for 44,200 shares. 20,649 are owned by Wms Prtn Ltd. Ruggie Cap Grp Inc holds 0.06% or 6,900 shares in its portfolio. Asset Management One holds 0% of its portfolio in MiMedx Group, Inc. (NASDAQ:MDXG) for 31,780 shares. Invesco Limited holds 297,093 shares or 0% of its portfolio.

Among 9 analysts covering MiMedx Group (NASDAQ:MDXG), 5 have Buy rating, 2 Sell and 2 Hold. Therefore 56% are positive. MiMedx Group has $21.0 highest and $9 lowest target. $15.25’s average target is 95.76% above currents $7.79 stock price. MiMedx Group had 30 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Needham with “Buy” on Friday, July 14. Needham maintained MiMedx Group, Inc. (NASDAQ:MDXG) on Wednesday, December 13 with “Buy” rating. The firm has “Outperform” rating by Northland Capital given on Friday, October 30. On Wednesday, December 13 the stock rating was maintained by Piper Jaffray with “Buy”. First Analysis maintained MiMedx Group, Inc. (NASDAQ:MDXG) on Wednesday, January 20 with “Overweight” rating. The rating was downgraded by Lake Street on Monday, February 26 to “Hold”. Needham maintained it with “Buy” rating and $21.0 target in Thursday, January 18 report. The rating was downgraded by Needham on Wednesday, July 29 to “Buy”. The stock has “Strong Buy” rating by Needham on Monday, November 16. The stock of MiMedx Group, Inc. (NASDAQ:MDXG) earned “Buy” rating by Lake Street on Tuesday, April 19.

MiMedx Group, Inc. (NASDAQ:MDXG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Richard Conner

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: